Abstract Library

#2793 A Phase II, Open-Label, Multicenter Trial of Avelumab in Patients with Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive after First-line Chemotherapy (AVENEC)

Introduction: High grade Neuroendocrine Neoplasias (NEN) are rare tumors with a poor prognosis and no established second line therapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Weber M

Authors: Fottner C, Apostolidis L, Ferrata M, Krug S, Michl P,

Keywords: NEC, NEN G3, check-point inhibitor, Avelumab, anti-PD-L1-antibody, immunotherapy,

#2769 Treatment Outcomes of Patients with G3 Neuroendocrine Neoplasms

Introduction: Extra-pulmonary neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) G3 are aggressive neoplasia associated with a limited prognosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Jann H

Authors: Schenk J, Kayser A, Wiedenmann B, Tacke F, Roderburg C,

Keywords: NEN G3, Chemotherapy, Platinum, NEC G3, NET G3,

#2740 Long-Term Complete Response in Metastatic Poorly-Differentiated Neuroendocrine Rectal Carcinoma with Multimodal Approach. A Case Report

Introduction: Rectal neuroendocrine carcinomas (NEC) are extremely rare and account for less than 1% of colorectal malignancies.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Della Torre S

Authors: Lombardi P, Grandi S, Marinelli M, Manara M, Della Torre S,

Keywords: rectal nec, net, chemotherapy, metastatic disease,

#2299 Expanding the WHO 2017 Classification to Gastrointestinal Tumors: Real-World Data from the R-GETNE Registry

Introduction: The update of the WHO 2017 classification of pancreatic neuroendocrine tumors (NETs) introduces the distinction between NET & NEC G3, based on histological differentiation. However, little is known about the possibility of extending this concept to non-pancreatic NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Castaño A, Capdevila J, Benavent M,

Keywords: WHO classification, NET G3, NEC G3, non-pancreatic NET, poorly differentiated,

#2279 Expression of FOXM1 in G3 Neuroendocrine Tumors (NET G3) and G3 Neuroendocrine Carcinomas (NEC G3) of the Pancreas and the Intestine

Introduction: G3 gastroenteropancreatic neuroendocrine tumors (G3 NET) and carcinomas (G3 NEC) differ considerably concerning their biological behavior and patients outcome. Whereas the WHO2017 classification for pancreatic NETs proposes a distinction of both groups using the Ki-67 proliferation marker (Klöppel et al. Reviews and Reports 2017), a useful marker for the subclassification of G3 intestinal NETs have not been recommended until now.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Briest F

Authors: Briest F, Konukiewitz B, Anlauf M, Klöppel G, Grabowski P,

Keywords: gastroenteropancreatic neuroendocrine tumors, GEP-NET, NET G3, NEC G3, Tumor marker, FOXM1, Ki-67, differentiation,